Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Global Research & Development Center US (TGRD US) has presented the results from pivotal phase 3 studies of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), demonstrating 24-hour systolic blood pressure (SBP) reduction compared to commonly prescribed ARBs olmesartan medoxomil and valsartan.
Subscribe to our email newsletter
Results were statistically significant and showed that azilsartan medoxomil (80 mg/day) lowered 24-hour SBP by ambulatory blood pressure monitoring (ABPM), the primary endpoint, in head-to-head trials with the highest approved doses of olmesartan medoxomil and valsartan in hypertensive patients.
Stuart Kupfer, executive medical director of Takeda clinical science, said: “We were encouraged at the results demonstrating azilsartan medoxomil achieved greater reductions in 24-hour mean systolic blood pressure when compared to two other commonly used ARBs at their respective maximum doses.
“Having new treatment options is important to potentially address the estimated 42 million hypertensive patients in the US who may not be adequately controlled and are at risk for other serious health problems.”